Icon

ZORYVE (nda215985)- (0.3%)

ROFLUMILAST ARCUTIS
0.3%
Yes No
2037-Aug-25 Expired
None 2025-Jul-29
None No
ZORYVE is a phosphodiesterase 4 inhibitor indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
0 0 0
Total Other Developers 5
Drugs with Suitability No
0.3% ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.